A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial
A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426008872?dgcid=rss_sd_all
A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426008872?dgcid=rss_sd_all
“A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.” Annals of Oncology.
@article{article88415,
title = {A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426008872?dgcid=rss_sd_all}
}
ABSTRACT Diagnosing and classifying platelet disorders (PD) is challenging in children. Therefore, we evaluated clinical, laboratory, and genetic data to improve current algorithms by performing a prospective observational cohort study...
Abstract Background and Objectives Perioperative blood transfusion in hip arthroplasty is associated with increased morbidity, prolonged hospitalization, and higher costs. This study aimed to identify independent risk factors and...